Viatris outlines long-term financial targets 2020-2030

What happened: Viatris, a global healthcare company, outlined its long-term financial targets for 2020-2030. It expects 5% to 6% total revenue CAGR, 7% to 8% adjusted EBITDA CAGR, 9% to 10% adjusted EPS CAGR, and $3 billion in annual free cash flow by 2030. Separately, VivoPower, a renewable energy company, initiated a share conversion program to reduce its public float and align management with long-term shareholder interests. Barclays analysts, meanwhile, upgraded Viatris to an Overweight rating and increased its price target to $17.

Market impact: Viatris' long-term targets drive investor optimism in the pharmaceutical sector. The company's expected growth in revenues and earnings per share (EPS) could attract more investors, potentially boosting its stock price. VivoPower's share conversion program may increase its stock's appeal to long-term investors, as it signals management's commitment to shareholder alignment.

What to watch next: Viatris' upcoming earnings reports, scheduled for April 28 and July 28, will provide insights into its progress towards its long-term targets. Additionally, investors should monitor VivoPower's share conversion program and its impact on the company's stock performance. Lastly, regulatory decisions and market reactions to Viatris' pipeline developments, such as its COVID-19 treatment Molnupiravir, will be crucial to follow.